Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP (clinicaltrials.gov) - Sep 25, 2026 - P2 | N=180 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting
Enrollment open • Cardiovascular • Coronary Artery Disease
|